

Evaluation of the optimal duration of immunosuppressive treatment after induction of remission, in patients with ANCA vasculitis

| | | |
|--|---|---|
| Submission date 04/01/2017 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 10/01/2017 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 30/05/2017 | Condition category Circulatory System | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Vasculitis is a condition in which the immune system attacks blood vessels by mistake, leading them to lead fluid into tissues causing inflammation (swelling). This happens because antibodies, which are normally produced by the immune system to fight germs, start attacking a type of white blood cell called neutrophils. In the case of ANCA vasculitis, the antibodies which are attacking the neutrophils are called Anti-Neutrophil Cytoplasmic Autoantibodies (ANCA). When ANCAs attack the neutrophils, the neutrophils in turn start to attack the walls of small blood vessels in different parts of the body. The treatment of ANCA vasculitis is by drugs which suppress the immune system (immunosuppressive drugs). These drugs, which include steroids, have side-effects and it is desirable to reduce the doses and stop them where possible. However vasculitis can return when the drugs are reduced or stopped. The aim of this study is to investigate how long immunosuppressive drugs should be given to patients with vasculitis.

Who can participate?

Adults with ANCA vasculitis which has been treated and is now under good control.

What does the study involve?

Participants are randomly allocated to one of two groups. In both groups, before they are allocated to the different groups, participants are taking immunosuppressive therapy, which involves taking the drug azathioprine and prednisolone every day by mouth for three months. Those in the first group then stop taking the azathioprine and lower the dose of prednisolone, which is stopped altogether by five months later. Those in the second group continue to take their azathioprine until the end of the study (30 months) and gradually reduce and eventually stop taking their prednisolone between 18 and 24 months. At the start of the study and then every three months until the end of the study (30 months), participants attend visits where they have blood samples taken to find out whether the vasculitis has come back and to assess their health.

What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?

1. Addenbrooke's Hospital (UK)
2. Hôpital Cochin (France)
3. Maastricht University (Netherlands)
4. Universitetssjukhuset Linköping (Sweden)
5. Uniklinikum Aachen (Germany)
6. Provincial Barcelona Hospital Hospital Clínic de Barcelona (Spain)

When is the study starting and how long is it expected to run for?

January 1994 to September 2012

Who is funding the study?

European Community (EC) BIOMED-1 Concerted Action Programme (UK)

Who is the main contact?

Prof. Alexandre Karras

alexandre.karras@aphp.fr

Contact information

Type(s)

Scientific

Contact name

Prof Alexandre Karras

ORCID ID

<http://orcid.org/0000-0002-3075-7739>

Contact details

Hôpital Européen Georges-Pompidou

Nephrology Department

20 Rue Leblanc

Paris

France

75015

+33 (0)1 56 09 37 60

alexandre.karras@aphp.fr

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

1

Study information

Scientific Title

Randomised controlled trial comparing relapse rate between standard (18 to 24 months) and prolonged (48 months) immunosuppression with azathioprine and prednisolone, in patients in the remission phase of ANCA vasculitis

Acronym

REMAIN

Study objectives

Prolonged maintenance therapy with low-dose prednisolone and azathioprine reduces long-term morbidity in systemic vasculitis, by reducing the frequency of relapse, when compared with cessation of therapy in the second year, as suggested by current guidelines.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NHS Executive North West MREC, 07/03/2001, ref: MREC/00/8/74

Study design

Prospective open-label randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

ANCA-associated vasculitis

Interventions

Patients with ANCA vasculitis in stable remission are included 18 to 24 months after initiation of immunosuppressive therapy. Patients are randomised in a 1:1 ratio to either withdraw from immunosuppression (Group W) or continue immunosuppression (Group C). Prior to randomisation, immunosuppressive therapy involves oral azathioprine at a daily dose of 1 mg/kg and oral prednisolone at the dose of 7.5 mg/day.

Group W: Participants receive oral azathioprine at the dose of 0.75 mg/kg for 3 months and then stop this drug. In addition, prednisolone is tapered to 5 mg/day at randomisation and then progressively stopped before month 5.

Group C: Participants continue oral azathioprine at the daily dose of 1 mg/kg for 30 months, until end of study. In addition, oral prednisolone is tapered to 5 mg/day at month 3, and then continued until month 18. After month 18, prednisolone is progressively stopped, before reaching month 24.

Duration of follow-up for both arms will be 30 months, with evaluation (examination and blood tests) every 3 months.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

1. Azathioprine 2. Prednisolone

Primary outcome measure

Rate of vasculitis relapse is measured using the Birmingham Vasculitis Activity Score (BVAS) continuously from baseline to 30 months.

Secondary outcome measures

1. Incidence of major and minor relapse is measured using the Birmingham Vasculitis Activity Score (BVAS) continuously from baseline to 30 months
2. Mortality rate is measured continuously from baseline to 30 months
3. Adverse events of therapy are observed continuously from baseline to 30 months
4. Cumulative damage is assessed using the Vasculitis Damage Index (VDI) from baseline to 30 months
5. Renal function is assessed by measuring estimated Glomerular Filtration Rate (eGFR) from baseline to 30 months
6. Incidence of end-stage renal disease (ESRD) is monitored from baseline to 30 months
7. ANCA status

Overall study start date

01/01/1994

Completion date

01/09/2012

Eligibility

Key inclusion criteria

1. Diagnosis of MPA, GPA or renal-limited vasculitis
2. Renal involvement and/or other threatened loss of function of a vital organ (lung, brain, eye, motor nerve, or gut); and ANCA positivity (ANCA-negative patients were eligible for enrollment in the study only when there was histologic confirmation of pauci-immune vasculitis)

3. Remission-induction therapy with cyclophosphamide and prednisolone for at least 3 months, with or without plasma exchanges
4. Stable remission on azathioprine/prednisolone
5. Aged 18 years and over

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

116

Key exclusion criteria

1. Age under 18 years
2. Pregnancy
3. Previous malignancy
4. Known HIV infection
5. Previous life-threatening relapse
6. End-stage renal disease (ESRD) at inclusion and allergy to study medications. Patients not in stable remission for at least six months at 18 months after commencement of therapy and patients who had discontinued azathioprine and/or prednisolone are excluded from the study.

Date of first enrolment

01/09/1998

Date of final enrolment

01/03/2010

Locations**Countries of recruitment**

Czech Republic

England

Finland

France

Germany

Italy

Lithuania

Netherlands

Spain

Sweden

Switzerland

United Kingdom

Study participating centre

Addenbrooke's Hospital

Lupus and Vasculitis Clinic
Hills Road
Cambridge
United Kingdom
CB2 0QQ

Study participating centre

Hôpital Cochin

Department of Internal Medicine
27 Rue du Faubourg Saint-Jacques
Paris
France
75014

Study participating centre

Maastricht University

Department of Immunology
Minderbroedersberg 4-6
Maastricht
Netherlands
6211 LK

Study participating centre

Universitetssjukhuset Linköping

Department of Nephrology
Universitetssjukhuset
Linköping
Sweden
581 85

Study participating centre
Uniklinikum Aachen
Department of Nephrology
Pauwelsstraße 30
Aachen
Germany
52074

Study participating centre
Provincial Barcelona Hospital Hospital Clínic de Barcelona
Nephrology Department
Carrer de Villarroel, 170
Barcelona
Spain
08036

Sponsor information

Organisation
European Vasculitis Society

Sponsor details
Box 57
Department of Renal Medicine
Addenbrooke's Hospital
Cambridge
United Kingdom
CB2 2QQ

Sponsor type
Research organisation

Website
<http://www.vasculitis.org/>

Funder(s)

Funder type
Research organisation

Funder Name

European Community (EC) BIOMED-1 Concerted Action Programme

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact reviewed journal.

Intention to publish date

31/12/2017

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Alexandre Karras (akarras3@gmail.com) or David Jayne (dj106@cam.ac.uk)

IPD sharing plan summary

Available on request

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/10/2017 | | Yes | No |